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Abstract
The prevalence of human papillomavirus (HPV) infections in
2109 females inhabiting ﬁve cities of Colombia was determined.
Of the 49.2% with an HPV infection, 59.8% were infected with
more than one viral type. Species 7 (of the the genus Alphapapil-
lomavirus) was associated with multiple infections. Analysis of the
socio-demographic data revealed a statistically signiﬁcant protec-
tive effect associated with the status of civil union (civil recogni-
tion of cohabitation without marriage), and indigenous ethnicity
proved to be a risk factor for HPV infection. This is the ﬁrst
study comparing HPV infection among women from geographical
regions of Colombia with different socio-cultural structures.
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Cervical cancer (CC) has been primarily associated with infec-
tion with high-risk human papillomavirus (HPV) (HR-HPV)
types, mainly with Alphapapillomavirus species 7 (HPV-18, HPV-
39, HPV-45, HPV-59 and HPV-68) and species 9 (HPV-16,
HPV-31, HPV-33, HPV-35, HPV-52, HPV-58 and HPV-67) [1].
Although prior HPV infection is a necessary step for the
development of CC, there are several other factors that can
increase the risk of developing CC, including age, number of
sexual partners, age at ﬁrst intercourse, pregnancies, smok-
ing habits, contraceptive methods, and co-infection with
other pathogens or different HPV types [2]. Co-infection
with other pathogens or different HPV types (which ranges
in frequency between 30% and 40% around the world [3,4])
especially contributes to the severity of the lesions.
Colombia is one of the countries with the highest inci-
dence of CC in the world, the disease affecting 23–48 indi-
viduals per 100 000 females, mainly those aged 30–39 years
[5]. The present study involved females from ﬁve geographi-
cal regions, where CC mortality rates ranged between 3.12
and 5.67 [6]: Leticia (Amazon jungle); Chaparral, mainly
inhabited by a mestizo population; Tumaco, where most of
the black females enrolled in this study live; Bogota, the
country’s capital; and Girardot, a tourist destination.
The study involved 2109 women (mean age 38.8 years),
attending a local CC prevention programme during 2007, from
the different regions as follows: 173 women from the League
Against Cancer (Leticia, south-east Colombia); 174 women
from the Hospital San Juan Bautista (Chaparral region); 921
women from the Hospital de Engativa (Bogota); 334 women
from the Nuevo Hospital San Rafael de Girardot-Cundinamar-
ca (central Colombia); and 508 women from the Hospital San
Andres de Tumaco-Narin˜o (south-west Colombia). Each
patient ﬁlled out a questionnaire regarding risk factors and
gave her signed consent. The study was supervised and
approved by each institution’s ethics committee.
All cervical epithelium samples were preserved in 95%
ethanol [7]. Samples were washed with phosphate-buffered
saline and digested in lysis buffer [8]. To assess cervical sam-
ple integrity, the human b-globin gene was ampliﬁed using
the GH20/PC04 primers, as previously described [9].
Samples yielding DNA of adequate quality were ampliﬁed
following two PCR protocols using consensus primers GP5+/
GP6+ and MY09/MY11 [10]. HPV DNA-positive samples,
according to one or both generic ampliﬁcation reactions, were
assessed by DNA ampliﬁcation with HR-HPV-16, HR-HPV-31,
HR-HPV-33, HR-HPV-45, HR-HPV-58 and HR-HPV-18 type-
speciﬁc primers [11–13]. The viral types HPV-16, HPV-31,
HPV-33 and HPV-58 were grouped into species 9, and viral
types HPV-18 and HPV-45 were grouped into species 7 [14].
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Owing to poor DNA quality, 295 samples were excluded.
Of the remaining samples, 921 (50.8%) were negative for
viral DNA. The 893 positive samples (49.2%) were included
in the statistical analysis. As shown in Table 1, the HPV-16
type (species 9) was the most prevalent in single infections
but appeared at the lowest rate in multiple infections.
Regarding species 7, HPV-18 was the second most preva-
lent type in single infections, whereas HPV-45 was found
only in multiple infections. These results agree with those of
previous reports showing that genotypes belonging to this
species are more often present in multiple infections than in
single infections [15].
The study revealed a higher viral prevalence and percent-
age of multiple infections than previous reports [4,16]. This
higher prevalence could be explained by the use of both viral
DNA ampliﬁcation primer sets, the MY09/11 system being
more efﬁcient in detecting viral DNA (38.8%) than the
GP5+/GP6+ set (17.3%) (data not shown). All viral types
assessed in this study had a higher prevalence when associ-
ated with multiple infections. Within the single-infection
group, HPV-16 was the most representative genotype, thus
contributing to the highest prevalence of species 9. The high
frequency of this type could not be attributed to the infec-
tion mechanism, as all HPV genotypes involved in the study
have the same transmission mechanism [17]. Nevertheless,
the analysis was clearly limited by the cross-sectional study
design, as it failed to accurately establish whether infection
with HPV-16 conferred a higher risk of concomitant infec-
tion with other viral types.
Associations between categorical variables (age, age at ﬁrst
intercourse, number of sexual partners, and number of preg-
nancies) were assessed using ORs and 95% CIs. ORs were
adjusted according to a logistic regression model, where the
presence or absence of co-infection was the main outcome
variable. All statistical procedures were performed using STA-
TA software.
TABLE 1. Distribution of human papillomavirus (HPV)







16 (46.2) 9 321 (38.3) 518 (61.7)
31 (15.9) 9 4 (1.4) 286 (98.6)
33 (10.6) 9 1 (0.52) 193 (99.5)
58 (5.1) 9 3 (3.2) 91 (96.8)
18 (14.7) 7 30 (11.2) 238 (88.8)
45 (9.4) 7 0 172 (100)
Total – 359 (40.2) 534 (59.8)
TABLE 2. Behavioural and socio-
demographic factors associated with











<25 49 (35.8) 88 (64.2) – –
26–40 154 (44.4) 193 (55.6) 0.71 (0.43–1.17) 0.71 (0.42–1.19)
>40 156 (38.1) 253 (61.9) 0.75 (0.42–1.3) 0.69 (0.38–1.26)
Pregnancies
None 23 (33.8) 45 (66.2) – –
1–2 120 (39.6) 183 (60.4) 1.01 (0.52–1.97) 1.05 (0.53–2.09)
3–4 136 (44.2) 172 (55.8) 0.84 (0.41–1.71) .86 (0.41–1.81)
>4 70 110 (61.1) 1.15 (0.53–2.47) 1.29 (0.58–2.88)
Sexual partners
1 145 (38.1) 236 (61.9) – –
2–3 156 (41.4) 221 (58.6) 0.78 (0.56–1.10) 0.82 (0.57–1.17)
>3 39 (42.9) 52 (57.1) 0.66 (0.381–1.14) 0.74 (0.40–1.23)
Contraceptive method
None 142 (39.9) 214 (60.1) – –
Hormonal 39 (39.8) 59 (60.2) 1.25 (0.61–2.56) 0.9 (0.66–1.46)
Surgery 110 (43.3) 144 (56.7) 1.01 (0.69–1.47) 0.77 (0.35–1.69)
Condom 15 (37.5) 25 (62.5) 0.89 (0.42–1.86) 1.16 (0.69–1.95)
Intrauterine device 41 (40.6) 60 (59.4) 1.01 (0.61–1.67) 0.60 (0.29–1.21)
Status
Single 43 (29.7) 102 (70.3) – –
Married 76 (37.1) 129 (62.9) 0.58 (0.32–1.04) 0.63 (0.34–1.17)
Civil union 204 (46.4) 236 (53.6) 0.55 (0.33–0.92) 0.57 (0.33–0.99)
Separated 25 (41) 36 (59) 0.52 (0.25–1.06) 0.49 (0.23–1.04)
Widowed 10 (37) 17 (63) 0.85 (0.3–2.41) 0.77 (0.25–2.34)
Ethnicity
White 37 (24.5) 114 (75.5) – –
Indigenous 6 (20) 24 (80) 1.83 (0.63–5.31) 3.30 (1.03–10.5)
Mestizo 212 (41.2) 303 (58.8) 0.57 (0.37–0.88) 1.44 (0.84–2.46)
Black 99 (54.7) 82 (45.3) 0.35 (0.20–0.58) 1.38 (0.65–2.94)
Age at ﬁrst intercourse (years)
<15 86 (41.7) 120 (58.3) – –
16–19 176 (39.6) 268 (60.4) 1.07 (0.73–1.57) 1.07 (0.73–1.57)
>19 82 (39) 128 (61) 1.00 (0.62–1.62) 1.00 (0.62–1.62)
Values in bold had p < 0.05.
aOR adjusted for age, number of pregnancies, age at ﬁrst intercourse, number of sexual partners, ethnicity, geo-
graphical region, and contraceptive method.
CMI Research Notes 101
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 93–102
When ORs were estimated without considering the geo-
graphical origin of the sample (Table 2), the status of civil
union (frequent in Colombia) and ethnicity (mestizo and
black) appeared to be the main signiﬁcant factors associated
with a lower risk of co-infection (taking single status and
white ethnicity, respectively, as references). When the ORs
were adjusted, the status of civil union remained a protective
factor, possibly due to the lower number of sexual partners
and the habitual use of oral contraceptive methods associated
with this status, as compared to the increased risk of sexual
behaviours associated with other statuses (e.g. single) [18].
Conversely, indigenous ethnicity proved to be associated
with a higher risk of co-infection once the ORs were adjusted,
possibly due to the vulnerability of this population related to
the conditions under which they live (poverty, deﬁcient diet,
unprotected sexual behaviour, poor access to adequate health
services, etc.) [19]. However, the higher risk may also be
related to intrinsic biological and cultural characteristics, or to
environmental factors associated with this ethnic group; these
possibilities were not taken into consideration in this study,
but should be analysed in further studies.
Previous studies in Colombian women involved mainly
urban populations with better access to health services and a
more uniform racial distribution, whereas this study analysed
different geographical regions and considered a more ethni-
cally diverse population. The differential geographical distri-
bution seen in this study stresses the importance of applying
HPV control measures in accordance with the HPV preva-
lance observed in each region.
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